abrdn plc acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,166,000. Separately, Pale Fire Capital SE bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $42,000. […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock. Separately, HC Wainwright reissued a buy rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Wednesday morning, RTT News reports. The firm currently has a $10.00 target price on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at ($0.23) EPS, […]
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Valneva (NASDAQ:VALN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership. Risk and Volatility TScan Therapeutics has a beta […]